AzTrials
AzTrials

Anterior Cruciate Ligament Partial RupturePhase 1/2NCT02469792

Effectiveness and Safety of Autologous ADRC for Treatment of Anterior Cruciate Ligament Partial Rupture

A Phase 1/2 study testing Liposuction, ADRC isolation and Arthroscopic surgery in people with Anterior Cruciate Ligament Partial Rupture, run by Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation at 1 site in Russia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Autologous adipose-derived regenerative cells (ADRC) will be extracted using Celution 800/CRS System (Cytori Therapeutics Inc) from a portion of the fat harvested from the patient's front abdominal wall. Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
Liposuction, ADRC isolation and Arthroscopic surgery
Could I receive a placebo?
No, everyone receives an active treatment
How many people
12 participants
Where
1 siteRussia
Study dates
Jun 2015to Dec 2018
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient suffers from partial rupture of anterior cruciate ligament (confirmed by MRI or knee arthroscopic surgery)
  • Clinically significant knee instability (positive anterior drawer test, pivot shift test, and Lachman test)
  • Patient is familiar with Participant information sheet
  • Patient signed informed consent form
  • Non-inclusion Criteria:
  • Knee osteoarthritis grade III and grade IV
Show all 20Show fewer
  • Medical history of autoimmune diseases
  • Patients prescribed for immunosuppressive treatment
  • Contraindications to the general or local anesthesia or medical history of allergic reactions to anesthetics
  • Subcompensated or decompensated forms of chronic diseases of internal organs
  • Significant weight loss (> 10% of body weight in the previous year) of unknown etiology
  • Medical history of venous thromboembolism or estimated high risk of venous thromboembolism
  • Clinically significant abnormalities in results of laboratory tests
  • Any conditions limiting compliance (dementia, neuropsychiatric disease, drug and alcohol abuse etc.)
  • Participation in other clinical trials (or administration of investigational drugs) during 3 months prior inclusion
  • Patients with malignant tumors including postoperative period, patients receiving chemotherapy and/or radiotherapy.
  • Patient's activated partial thromboplastin time exceeds normal levels more than 1,8 times
  • Patients prescribed for anticoagulants treatment or patient received anticoagulants at least one hour prior lipoaspiration
  • Medical history of heterotopic ossifications
  • Patients prescribed for glycoprotein inhibitors treatment

Who cannot join

  • Patient's refusal from the further participation in trial
  • Patient's refusal from compliance with the requirements of contraception during the participation in research
  • Chronic kidney disease IV - V stages (creatinine clearance < 30 mL/min estimated by Cockroft-Gault formula)
  • Confirmed syphilis, HIV, hepatitis B or C infections
  • Dropout Criteria:
  • Complete anterior cruciate ligament rupture confirmed by knee arthroscopic surgery
  • Pregnancy

Trial locations and contacts

1 site in 1 country.

Russia1 site

  • Federal State Budgetary Institution "Central Clinical Hospital with Outpatient Health Center" of the Business Administration for the President of the Russian Federation; Center for Biomedical Technologies

    Moscow, 121359

Other trials in Russia

About this study

Official title: Effectiveness and Safety of Intraarticular Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Anterior Cruciate Ligament Partial Rupture

Autologous adipose-derived regenerative cells (ADRC) will be extracted using Celution 800/CRS System (Cytori Therapeutics Inc) from a portion of the fat harvested from the patient's front abdominal wall. Patients will undergo knee arthroscopic surgery followed by one-time intraarticular ADRC administration (directly into anterior cruciate ligament). This is a single arm study with no control. All patients receive cell therapy.

Read the detailed description

Patients with verified diagnosis partial rupture of anterior cruciate ligament will undergo liposuction from front abdominal wall under local anesthesia. After that autologous ADRC will be extracted using Celution 800/CRS System (Cytori Therapeutics Inc) from harvested adipose tissue. Same day patients will undergo knee arthroscopic surgery followed by one-time intraarticular freshly isolated ADRC administration (directly into anterior cruciate ligament close to the rupture).

Being tested
Liposuction, ADRC isolation, Arthroscopic surgery, Intraarticular administration of autologous ADRC
Keywords
Anterior cruciate ligament, Ligament rupture, Intraarticular injection, ADRC, Adipose-derived regenerative cells, Adipose tissue, Stem cells

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LiposuctionProcedure or surgery

  • ADRC isolationDevice

    ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol

  • Arthroscopic surgeryProcedure or surgery

  • Intraarticular administration of autologous ADRCOther

Study groups in NCT02469792
Study groupRoleWhat they receive
ADRC injectionExperimentalSubjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected intraarticularly into anterior cruciated ligament.
Receives: Procedure: Liposuction; Device: ADRC isolation; Procedure: Arthroscopic surgery; Other: Intraarticular administration of autologous ADRC

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of serious adverse events (SAEs) and serious adverse reactions (SARs)

    Measured: 2 weeks after treatment

Secondary outcomes (4)

  1. Quality of life monitoring

    Quality of life estimated by validated questionnaires: the Short Form (36) Health Survey (SF-36), Knee Injury and Osteoarthritis Outcome Score (KOOS)

    Measured: Follow up to completion (up to 24 weeks after treatment)

  2. Knee pain intensity monitoring

    Knee pain intensity assessed by Visual Analogue Scale (no pain=0; maximum pain=100 mm)

    Measured: Follow up to completion (up to 24 weeks after treatment)

  3. Changes in knee joint structures

    Changes in knee joint structure assessed by:

    1. X-ray (joint space width, bone contour, presence of osteophytes and sclerosis);
    2. MRI (articular cartilage, osteophytes, bone marrow abnormality, meniscal integrity, synovial effusion/tissue, anterior and posterior cruciate ligaments, and medial and lateral collateral ligaments);
    3. Ultrasonography (effusion, synovial thickening or hypertrophy, cartilage parameters, vascularity, Baker's cysts, osteophytes, tendon and ligament abnormalities, meniscal changes, bursitis, erosions and panniculitis)

    Measured: Follow up to completion (up to 24 weeks after treatment)

  4. Changes in knee function

    Changes in knee function assessed by questionnaire: Knee Society Score (KSS)

    Measured: Follow up to completion (up to 24 weeks after treatment)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jun 2015 (estimated)
  2. Study startJun 2015
  3. Primary completionJun 2018 (estimated)
  4. Study completionDec 2018 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
12 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02469792
Sponsor's protocol ID
RU-CCH-03-01-14
Status last verified
Jul 2017
First submitted
9 Jun 2015
Last updated
21 Jul 2017
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Liposuction, ADRC isolation and Arthroscopic surgery in people with Anterior Cruciate Ligament Partial Rupture, run by Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation at 1 site in Russia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 20 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Jul 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of serious adverse events (SAEs) and serious adverse reactions (SARs) (time frame: 2 weeks after treatment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02469792.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2017.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in